GARY ALAN CLAWSON
Medical Practice in Bethesda, MD

2004022, Nov 4, 2004

May 27, 2003

10/257480

James Norris - Mt. Pleasant SC, US
Caroline Westwater - Mt. Pleasant SC, US
David Schofield - Mt. Pleasant SC, US
Michael Schmidt - Charleston SC, US
Brian Hoel - James Island SC, US
Joseph Dolan - Mt. Pleasant SC, US
Gary Clawson - Bethesda MD, US
Wei-Hua Pan - Hummelstown PA, US

A61K048/00

514/044000

The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agent to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention has important implications in the eradication of drug-resistant pathogens (such as antibiotic resistant bacteria) and drug-resistant diseased cells (such as drug-resistant cancer cells).

2006022, Oct 5, 2006

Mar 13, 2006

11/375690

James Norris - Mt. Pleasant SC, US
Caroline Westwater - Mt. Pleasant SC, US
David Schofield - Mt. Pleasant SC, US
Michael Schmidt - Charleston SC, US
Brian Hoel - James Island SC, US
Joseph Dolan - Mt. Pleasant SC, US
Gary Clawson - Bethesda MD, US
Wei-Hua Pan - Hummelstown PA, US

A61K 48/00, C07H 21/02

514044000, 536023100

The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention has important implications in the eradication of drug-resistant pathogens (such as antibiotic resistant bacteria) and drug-resistant diseased cells (such as drug-resistant cancer cells).

7575918, Aug 18, 2009

Sep 8, 2004

10/935962

James Norris - Mt. Pleasant SC, US
Gary Clawson - Bethesda MD, US
Caroline Westwater - Mt. Pleasant SC, US
David Schofield - Mt. Pleasant SC, US
Michael G. Schmidt - Charleston SC, US
Brian Hoel - Charleston SC, US
Joseph Dolan - Mt. Pleasant SC, US
Wei-Hua Pan - Hummelstown PA, US

The Penn State Research Foundation - University Park PA

C07H 21/04, C07H 21/02, C12Q 1/68, A61K 31/70

4353201, 435 6, 536 231, 536 241, 536 245, 514 44

The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen.

6271359, Aug 7, 2001

Apr 14, 1999

9/291902

James Norris - Mt. Pleasant SC
Gary Clawson - Bethesda MD
Caroline Westwater - Mt. Pleasant SC
David Schofield - Mt. Pleasant SC
Michael Schmidt - Mt. Pleasant SC
Brian Hoel - Charleston SC
Joseph Dolan - Mt. Pleasant SC
Wei-Hua Pan - Hummelstown PA

MUSC Foundation for Research Development - Charleston SC
The Penn State Research Foundation - University Park PA

C07H 2102, C07H 2104, C12N 1500

536 231

The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen.

7732197, Jun 8, 2010

Feb 26, 2002

10/082973

James S. Norris - Mt. Pleasant SC, US
Gary A. Clawson - Bethesda MD, US
Michael G. Schmidt - Mt. Pleasant SC, US
Brian Hoel - Charleston SC, US
Wei-Hua Pan - Hummelstown PA, US
Joseph W. Dolan - Mt. Pleasant SC, US

The Penn State Research Foundation - University Park PA
MUSC Foundation for Research Development - Charleston SC

C07H 21/02, C07H 21/04, A61K 31/70, C12Q 1/08, C12N 5/00, C12N 15/00

435325, 424450, 4353201, 435375, 536 231, 536 232, 536 241, 536 245, 514 44 R

The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present invention relates to the use of virions and viral vectors to package and deliver DNA encoding the multi-ribozymes to a host. The present invention relates to the use of liposomes and lipid-DNA complexes to deliver DNA encoding ribozymes to a host. Most specifically, the invention relates to the use of target specific virions to package and deliver DNA comprising a target specific promoter and encoding a ribozyme(s) directed to the target organism nucleic acids. The present invention further relates to a novel vectors encoding a multi-ribozyme structure with enhanced 5′ and/or 3′ autocatalytically cleaving ribozymes. The invention further relates to nucleotides encoding a multi-ribozyme comprising one or more ribozyme cassettes which contain one or more trans-acting ribozymes and one or more autocatalytically cleaving ribozyme sequences.

2004020, Oct 21, 2004

Feb 6, 2004

10/433542

Gary Clawson - Bethesda MD, US
Wei-Hua Pan - Hummelstown PA, US

C12Q001/68

435/006000

The invention provides improved library selection procedures for nucleic acids which allow the rapid determination of accessible target sites throughout relatively long target RNAs. This invention provides an improved method of screening a library of nucleic acids to identify cleavage sites of a target RNA. The steps of the screening comprise generating the library of nucleic acids, wherein each nucleic acid comprises a catalytic core flanked by random nucleotides; adding said target RNA to the library of nucleic acids; and isolating nucleic acids that cleave said target RNA. The nucleic acids selected by the methods described herein are also provided in the invention.

2010003, Feb 11, 2010

Oct 13, 2009

12/578035

Gary A. Clawson - Bethesda MD, US
Wei-Hua Pan - Hummelstown PA, US
Ping Xin - Hummelstown PA, US

C07H 21/02, C07H 21/04

536 245

The invention provides isolated nucleic acids. For example, the invention provides isolated nucleic acids having at least one strand with both sense and antisense sequences that are complementary to each other. The invention also provides isolated nucleic acids having at least one strand that is a template for both sense and antisense sequences that are complementary to each other. In addition, the invention provides cells, viruses, and transgenic animals (e.g., transgenic non-human animals) containing one or more of the isolated nucleic acids provided herein as well as methods for using one or more of the isolated nucleic acids provided herein to reduce the level of an RNA (e.g., an mRNA) within a cell.

7402561, Jul 22, 2008

Mar 9, 2005

11/076680

Gary Clawson - Bethesda MD, US
Craig Meyers - Hummelstown PA, US
David Drubin - Jamaica Plain MA, US
Molly McLaughlin-Drubin - Jamaica Plain MA, US

Clawnor, Inc. - Bethesda MD

A01N 37/18

514 2, 530300, 5303883, 435213, 524 9464, 514934

In the US about ⅓ of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.

7704965, Apr 27, 2010

Jun 26, 2003

10/519122

Gary A. Clawson - Bethesda MD, US
Wei-Hua Pan - Hummelstown PA, US
Diane Thiboutot - Hershey PA, US
Neil Christensen - Harrisburg PA, US

The Penn State Research Foundation - University Park PA

A61K 31/70, C07H 21/02, C07H 21/04, C12Q 1/68, C12N 5/00

514 44, 536 231, 536 2372, 536 241, 536 245, 435 6

The invention provides methods and materials related to treating HPV infections (e. g. , HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e. g. , cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers).